

C. P. 3950 Lévis (Québec) G6V 8C6 desjardinslifeinsurance.com/planmember Tel.: 1-844-410-6485

Fax: 1-877-838-2134 418-838-2134

PRIOR AUTHORIZATION REQUEST CABOMETYX (CABOZANTINIB)

PLEASE READ THE INSTRUCTIONS ON THE LAST PAGE OF THIS FORM.

Α	PATIENT IDENTIFICATI	ON – To be completed by the me	mber.									
	Patient's last and first name	2		Relations	hip wi	ith member		Patient's da				
				☐ Memb	er	\square Spouse	Dependent chi		MM DD			
	Member's last and first name					Contract No.		Certificate No.				
	No., street, apt. City							Province	Postal code			
	Telephone Nos – Home: Office:				ensio		Email:					
	Telephone Nos – Home:											
	Since the response to this request includes confidential information, please indicate how you would like to be informed of the decision: By mail (The response to your request will be sent to the address indicated in this section.) By fax:											
	Coordination of benefits: If the patient has coverage under a private insurance plan or is enrolled in a provincial drug insurance plan, please submit the request to this plan first. Then send us a copy of the decision notice and this form filled out by the physician, so we can analyze the request.											
		Does the patient have drug co	verage under a private	insurance p	lan?							
		Yes – Please provide a copy	of the notice of approv	val or refusa	al. –	→ □Сору	attached to this for	m.				
	PRIVATE PLAN	Specify: Name of the insurer:				Contract No.	•	Certificate No	ı.•			
		No										
	Has a request for reimbursement been submitted under your provincial plan?											
B1	PROVINCIAL PLAN	Yes − Please provide a copy of the notice of approval or refusal. → Copy attached to this form.										
		No – Please explain:										
		Is the patient enrolled in a pat	ient support program?	Yes	☐ No	1						
	PATIENT SUPPORT	If so – Program name:										
	PROGRAM	Contact person:				Telephon	e No.:		Extension:			
В1	DECLARATION AND AU	THORIZATION FOR THE CO	LECTION AND CON	MUNICA	TION	•		ON				
	Insurance, strictly for the purposes of managing my file and settling this claim to: (a) collect from any person or legal entity, or from any public or parapublic organization, only the information deemed necessary to manage my file. The non-exhaustive list of sources from which information may be collected includes healthcare professionals or facilities, and insurance companies; (b) communicate to the said persons or organizations only the personal information about me that is deemed necessary for the purposes of my file; (c) when necessary use the personal information it may have about me in existing files that are now closed. This authorization is also valid for the collection, use and communication of personal information concerning my dependents, insofar as applicable to the claim. A photocopy of this authorization is as valid as the original.											
>	Signature of member: Date:											
D 3	Signature of patient or parent/legal guardian (if applicable): CONSENT TO THE COMMUNICATION OF PERSONAL INFORMATION TO A THI				Date:							
DZ	To help us process your cla	aim more efficiently, do you auth f the reasons for the decision on y	orize Desjardins Insura	ance to info			port program and t	he attending phy	sician or the attending			
>	Signature of member: Date:											
	Last name and first name of parent/legal guardian (if applicable):											
	Signature of patient or parent/legal guardian (if applicable): Date:											
С	ATTENDING PHYSICIAN SECTION – To be completed by the attending physician.											
	Physician's last and first name (PLEASE PRINT)				icense	e No.	Specialty					
	No., street, suite City							Province	Postal code			
	Telephone No.: Fax No.:											
>	Signature of physician:						Date:					
Ť	Drug name		Formulation S	trength	D	osage	Scheduled durati	on of treatment				
	Where is the drug administered?											
	Other (please specify):											
		Deciarding Incomes	a refere to Decisadia	c Financial	C ~ ~ · ·	rity Life Accus	rance Compani					

C ATTENDING PHYSICIAN SECTION – Continued

- Make sure to fill out all sections so we can process the request faster. If any information is missing, we will send the form back to the member.
 In order to consider any diagnosis not mentioned on this form, we need supporting documents (clinical practice guidelines, clinical studies, etc.) that justify the drug's use in the given context.

DIAGNOSIS								
Advanced or metastatic rena	al cell carcinoma							
Unresectable hepatocellular	r carcinoma							
Locally advanced or metasta	atic differentiated thyroid o	carcinoma (DTC)						
Other therapeutic indication	n(s) – Please specify:							
FORMATION RELATING TO	ADVANCED OR METAST	TATIC RENAL CELL CARCINOMA						
This treatment will be given: \Box As monotherapy		☐ In association						
OG performance status:								
FORMATION RELATING TO	UNRESECTABLE HEPATO	DCELLULAR CARCINOMA						
his treatment will be given: \Box As monotherapy		☐ In association						
ild-Pugh class:								
OG performance status:								
FORMATION RELATING TO	LOCALLY ADVANCED OF	R METASTATIC DIFFERENTIATED THYROID CARCINOMA (DTC)						
is treatment will be given:	\square As monotherapy	☐ In association						
e cancer is:	\square Locally advanced	☐ Metastatic						
OG performance status:								
IN THE PROPERTY OF THE PROPERT		ent for this medical condition?						
• •	already used or any treat	ment already received for this medical condition:						
MEDICATION OR TREATMENT NAME		ОИТСОМЕ	TREATMENT PERIOD					
Name:		Inefficiency Intolerance Contraindication	From:					
Dose:		Specify:	YYYY MM DD					
Name:		Inefficiency Intolerance Contraindication	YYYY MM DD From:					
Dose:		Specify:	YYYY MM DD					
Name:		Inefficiency Intolerance Contraindication	YYYY MM DD From:					
Dose:		Specify:	YYYY MM DD					
Name:		Inefficiency Intolerance Contraindication	YYYY MM DD From:					
Dose:		Specify:	YYYY MM DD					
RESCRIPTION RENEWAL								
	hat shows a satisfactory cl	inical or biological response:						
	,							

D INSTRUCTIONS - HOW TO COMPLETE AND RETURN THIS FORM

- 1. Complete sections A and B.
- 2. Ask your physician to complete section C. The member is responsible for assuming any costs incurred to complete this form or to obtain additional information.
- 3. To obtain a reimbursement once the drug has been approved, please use your payment card at the pharmacy or submit your original receipts by mail. Eligible drugs must be dispensed by a pharmacist or a physician, if there is no pharmacist.

4. Send form: • by fax: Desjardins Insurance

Group Insurance, Health Claims,

418-838-2134 or 1-877-838-2134 (toll-free)

• by mail: Designins Insurance

Group Insurance, Health Claims
C. P. 3950, Lévis (Québec) G6V 8C6

Under its prior authorization program, Desjardins Insurance authorizes the reimbursement of certain drugs that meet criteria that are based, in particular, on clinical practice guidelines and recommendations issued by health technology assessment organizations. The drug will be eligible for reimbursement if it meets the insurer's criteria, if it's not administered in a hospital and if it's not eligible under a government program. If the information on your form is complete, your request will normally be processed within 5 business days.

When the request form is received, it will be assessed in the strictest confidence. In some situations, additional diagnostic or clinical information may be required.

If the treatment continues beyond the authorized period, you will be asked to submit a new request form and provide information that justifies the extension of treatment. If you have a payment card, your pharmacist will be advised that the authorization period is coming to an end. The insurance must be in force and the patient still covered on the date expenses are incurred. This prior authorization is subject to change if, at the time expenses are incurred, the contract has been modified.

When Desjardins Insurance declines a prior authorization request, it is because we need to uphold conditions set out in the contract. It does not mean we are questioning the physician's opinion. If you have any questions, please contact our Customer Contact Centre at the number indicated on page 1 of this form.